2269 Stoklara Genel Bakış Bir yatırım holding şirketi olan WuXi Biologics (Cayman) Inc. Çin Halk Cumhuriyeti, Kuzey Amerika, Avrupa, Singapur, Japonya, Güney Kore ve Avustralya'da biyolojik ilaç endüstrisi için biyolojik ilaç keşfi, geliştirilmesi ve üretimi için uçtan uca çözümler ve hizmetler sunmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
WuXi Biologics (Cayman) Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti WuXi Biologics (Cayman) Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$16.48 52 Haftanın En Yüksek Seviyesi HK$33.40 52 Haftanın En Düşük Seviyesi HK$10.14 Beta 0.57 1 Aylık Değişim -13.26% 3 Aylık Değişim -8.55% 1 Yıllık Değişim -41.14% 3 Yıllık Değişim -82.23% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -78.57%
Son Haberler & Güncellemeler
WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718). Oct 25
Investor sentiment deteriorates as stock falls 16% Oct 11
WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom Oct 05
First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023) Sep 22
Investor sentiment improves as stock rises 16% Sep 20
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing Aug 30 Daha fazla güncelleme görün
WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718). Oct 25
Investor sentiment deteriorates as stock falls 16% Oct 11
WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom Oct 05
First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023) Sep 22
Investor sentiment improves as stock rises 16% Sep 20
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing Aug 30
First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023) Aug 22
WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024 Jul 25
CEO & Executive Director recently sold HK$6.6m worth of stock Jun 18
Investor sentiment deteriorates as stock falls 16% May 27
Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022) Apr 30
Less than half of directors are independent Apr 11
Wuxi Biologics (Cayman) Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer Apr 03
WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024 Mar 27
Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022) Mar 27 WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700
New major risk - Share price stability Mar 14
Investor sentiment deteriorates as stock falls 17% Mar 11
WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024 Feb 15
Investor sentiment deteriorates as stock falls 18% Feb 14
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland Feb 01
Investor sentiment deteriorates as stock falls 19% Jan 30
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect Jan 25
Independent Non-Executive Director recently bought HK$3.0m worth of stock Jan 24
WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™ Jan 17
WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024 Jan 16
Investor sentiment improves as stock rises 16% Jan 15 WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023. Dec 08
New minor risk - Share price stability Dec 06
Investor sentiment deteriorates as stock falls 28% Dec 04
CEO & Executive Director recently sold HK$6.0m worth of stock Nov 23
Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale Nov 22
Now 21% undervalued Nov 17
Board Member recently sold HK$25m worth of stock Nov 15
Now 21% undervalued Oct 18
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality Oct 17
Investor sentiment improves as stock rises 16% Oct 12
First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022) Aug 24
Wuxi Biologics (Cayman) Inc. Announces Executive Changes Aug 17
WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023 Jul 26
CEO & Executive Director recently sold HK$4.6m worth of stock Jul 20
Investor sentiment deteriorates as stock falls 20% Jun 22
CEO & Executive Director recently sold HK$13m worth of stock Jun 16
Now 21% undervalued after recent price drop Jun 12 WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023 May 25
WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee May 18
Now 20% undervalued after recent price drop May 13
WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes May 09
Now 20% undervalued after recent price drop Apr 25
Investor sentiment improves as stock rises 16% Apr 14
Now 20% undervalued after recent price drop Apr 04
Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021) Mar 24 WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023
Investor sentiment improved over the past week Jan 03
Now 22% undervalued after recent price drop Dec 08
WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company Nov 26
CEO & Executive Director recently sold HK$6.0m worth of stock Nov 25
Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee Nov 24
Less than half of directors are independent Nov 16
Investor sentiment improved over the past week Nov 07
Investor sentiment deteriorated over the past week Oct 21
WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022. Oct 01
WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA Sep 20
Investor sentiment deteriorated over the past week Sep 14
First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021) Aug 19
WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee Aug 18
Now 21% undervalued Aug 03 WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022
CEO & Executive Director recently sold HK$17m worth of stock Jun 17
Investor sentiment improved over the past week Jun 09
Investor sentiment deteriorated over the past week May 07
Full year 2021 earnings released: EPS: CN¥0.81 (vs CN¥0.43 in FY 2020) Apr 30
Less than half of directors are independent Apr 27
Investor sentiment deteriorated over the past week Mar 08
Investor sentiment deteriorated over the past week Feb 09 Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021
CEO & Executive Director recently bought HK$18m worth of stock Jan 15
CEO & Executive Director recently bought HK$21m worth of stock Dec 23
WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5 Nov 24
CEO & Executive Director recently bought HK$39m worth of stock Nov 06
First half 2021 earnings released: EPS CN¥0.44 (vs CN¥0.19 in 1H 2020) Aug 26
WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021 Jul 15
CEO & Executive Director recently sold HK$300m worth of stock Jun 30
CEO & Executive Director recently sold HK$34m worth of stock Jun 16 WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.
Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019) Apr 30
Insider recently bought HK$3.4m worth of stock Mar 31
Full year 2020 earnings released Mar 24
WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group. Mar 19
WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd. Mar 17 Hissedar Getirileri 2269 HK Life Sciences HK Pazar 7D -6.2% -6.8% -4.3% 1Y -41.1% -34.4% 17.2%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 2269 geçen yıl % -34.4 oranında getiri sağlayan Hong Kong Life Sciences sektörünün gerisinde kaldı.
Getiri vs Piyasa: 2269 geçen yıl % 17.2 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 2269's price volatile compared to industry and market? 2269 volatility 2269 Average Weekly Movement 7.5% Life Sciences Industry Average Movement 8.5% Market Average Movement 6.9% 10% most volatile stocks in HK Market 14.6% 10% least volatile stocks in HK Market 3.2%
İstikrarlı Hisse Senedi Fiyatı: 2269 son 3 ayda Hong Kong piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 2269 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Bir yatırım holding şirketi olan WuXi Biologics (Cayman) Inc. Çin Halk Cumhuriyeti, Kuzey Amerika, Avrupa, Singapur, Japonya, Güney Kore ve Avustralya'da biyolojik endüstrisine yönelik biyolojik keşif, geliştirme ve üretim için uçtan uca çözümler ve hizmetler sunmaktadır. İki segment üzerinden faaliyet göstermektedir: Biyolojik Ürünler ve XDC. Şirket, WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI ve WuXiHigh dahil olmak üzere sözleşmeli araştırma, geliştirme ve üretim organizasyonu platformları aracılığıyla CMC ve aşağı akış süreç geliştirmeye sorunsuz bir şekilde geçiş yapan, konseptten IND'ye kadar biyolojik keşif için bir dizi çözüm sunmaktadır.
Daha fazla göster WuXi Biologics (Cayman) Inc. Temel Bilgiler Özeti WuXi Biologics (Cayman)'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 2269 temel i̇stati̇sti̇kler Piyasa değeri HK$67.66b Kazançlar(TTM ) HK$2.79b Gelir(TTM ) HK$18.16b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 2269 gelir tablosu (TTM ) Gelir CN¥17.12b Gelir Maliyeti CN¥10.50b Brüt Kâr CN¥6.62b Diğer Giderler CN¥3.99b Kazançlar CN¥2.63b
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/08 05:33 Gün Sonu Hisse Fiyatı 2025/01/08 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları WuXi Biologics (Cayman) Inc. 55 Bu analistlerden 24, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Linda Lu BOCI Research Ltd. Wai Chak Yuen BOCI Research Ltd. Bo Li BofA Global Research
Göster 52 daha fazla analist 
